• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

LATE-BREAKING ABSTRACT: Study to understand mortality and morbidIty in COPD (SUMMIT)
Chronic obstructive pulmonary disease (COPD) is recognized as having significant systemic manifestations associated with increased mortality and morbidity (Agusti, Proc Am Thorac Soc 2005;2:367-70), in particular cardiovascular (CV) disease. More patients with moderate COPD die from lung cancer and CV diseases than from COPD (Calverley, N Engl J Med 2007;356:775-89).Post-hoc analyses from the TORCH study suggest an inhaled corticosteroid/long acting beta2 agonist (ICS/LABA) combination may reduce mortality and CV events (e.g. acute coronary syndrome [ACS] and stroke) in patients with moderate COPD (≥50% predicted FEV1) ...
Source: European Respiratory Journal - October 30, 2015 Category: Respiratory Medicine Authors: Vestbo, J., Anderson, J., Brook, R. D., Calverley, P., Celli, B., Crim, C., Martinez, F., Yates, J., Newby, D. Tags: 1.1 Clinical Problems Source Type: research

Long-acting bronchodilator initiation in COPD and cardio-pulmonary risks: A population-based comparative effectiveness study
Long-acting bronchodilators, including long-acting beta2-agonists (LABA) and the anticholinergic tiotropium, are recommended as initial maintenance treatment in COPD, though their risk on cardio-pulmonary events remains uncertain in real world settings. We assessed whether treatment initiation with tiotropium increases the risk of acute myocardial infarction (AMI), stroke, heart failure, arrhythmia and pneumonia, relative to a LABA.We identified all new users of a long-acting bronchodilator during 2002-2012, age 55 or older, from the United Kingdom's Clinical Practice Research Datalink. Each patient who initiated tiotropiu...
Source: European Respiratory Journal - November 7, 2016 Category: Respiratory Medicine Authors: Suissa, S., Dell'Aniello, S., Ernst, P. Tags: 5.1 Airway Pharmacology and Treatment Source Type: research

Pulse wave velocity (PWV) in patients (pts) with moderate COPD and cardiovascular risk: The effect of an inhaled long-acting {beta}2-agonist/corticosteroid (SUMMIT)
Conclusion: In moderate COPD pts with or at high-risk of CVD, baseline PWV was predictive of mortality and CV events but unaffected by inhaled therapy.GSK Funded: 113782/NCT01313676.
Source: European Respiratory Journal - November 7, 2016 Category: Respiratory Medicine Authors: Crim, C., Brook, R., Anderson, J., Kilbride, S., Calverley, P., Celli, B., Martinez, F., Vestbo, J., Yates, J., Newby, D. Tags: 5.1 Airway Pharmacology and Treatment Source Type: research

Late Breaking Abstract - Inhaled corticosteroids (ICS), blood eosinophils (EOS), and FEV1 decline in patients with Chronic Obstructive Pulmonary Disease in a large UK primary healthcare setting
Conclusions: Regardless of blood EOS level, ICS-containing medication is associated with slower rates of FEV1 decline in COPD patients.Funding: GSK study 208602
Source: European Respiratory Journal - November 19, 2018 Category: Respiratory Medicine Authors: Whittaker, H., Mullerova, H., Jarvis, D., Barnes, N., Jones, P., Compton, C., Kiddle, S., Quint, J. Tags: Epidemiology Source Type: research

The relationship between eosinophils and reduction in major adverse cardiac events in ETHOS
Conclusion: Overall, there were fewer MACE in ICS-containing therapy groups than GFF. While event numbers were low, benefits of BGF vs GFF on CV death and non-fatal MI related to higher baseline EOS were consistent with the reduction in ACM with increasing EOS previously observed (Martinez, F.J. et al. Am J Respir Crit Care Med 2020. Epub ahead of print).
Source: European Respiratory Journal - November 25, 2021 Category: Respiratory Medicine Authors: Bafadhel, M., Rabe, K. F., Singh, D., Jenkins, M., Dorinsky, P., Patel, M. Tags: Airway pharmacology and treatment Source Type: research

Association of COPD exacerbations with cardiovascular events - a population-based cohort study
Conclusion: Severe exacerbations were associated with increased odds of CV events, which in the majority of patients occurred within 30 days after an exacerbation. This highlights that prevention of exacerbations in patients with COPD and concomitant CVD will improve both respiratory and CV health.
Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Lokke, A., Lange, P., Ibsen, R., Telg, G., Lykkegaard, J., Hilberg, O. Tags: 06.02 - Occupational and environmental health Source Type: research

Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis
Conclusion Compared with ICS/LABA, dual LAMA/LABA or triple therapy increases cardiovascular risk in patients with COPD. This should be considered in the context of the incremental benefits of these therapies for symptoms and exacerbation rates in patients with COPD, especially in those with a MACE risk of >1% per year.
Source: European Respiratory Journal - February 9, 2023 Category: Respiratory Medicine Authors: Yang, M., Li, Y., Jiang, Y., Guo, S., He, J.-Q., Sin, D. D. Tags: COPD and smoking Original Articles: COPD Source Type: research